Related Experiment Videos
Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis
G W Kaatz1, S M Seo, J R Aeschlimann
1Department of Internal Medicine, School of Medicine, Department of Veteran's Affairs Medical Center, Wayne State University, Detroit, Michigan 48201, USA. gkaatz@juno.com
Abstract:
The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureus endocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.
Insights
The novel glycopeptide antibiotic LY333328 demonstrated in vivo efficacy comparable to vancomycin in treating methicillin-resistant Staphylococcus aureus endocarditis in rabbits. This suggests LY333328 as a potential alternative therapeutic option.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat in healthcare settings.
- Endocarditis is a severe infection of the heart lining, often caused by S. aureus.
- Vancomycin is a primary antibiotic for MRSA infections, but resistance and toxicity are concerns.
Purpose of the Study:
- To evaluate the in vivo efficacy of LY333328, a new glycopeptide antibiotic.
- To compare LY333328 directly with vancomycin in a relevant animal model of infection.
Main Methods:
- The study utilized a rabbit model of left-sided endocarditis caused by MRSA.
- Animals were treated with either LY333328 or vancomycin for 4 days at specified dosages.
- Efficacy was assessed by measuring bacteremia, and bacterial counts in vegetations and tissues.
Main Results:
- Both LY333328 and vancomycin effectively cleared bacteremia.
- Both antibiotics significantly reduced bacterial counts in cardiac vegetations and other tissues.
- No significant difference in microbiological efficacy was observed between the two drugs in this model.
Conclusions:
- LY333328 exhibits comparable microbiological efficacy to vancomycin in the rabbit model of MRSA endocarditis.
- LY333328 represents a potential therapeutic alternative for treating MRSA infections.
- Further clinical investigation is warranted to confirm its therapeutic value.